Lubiprostone

FDA Approved: * November 30, 2021
Pharm Company: * AMNEAL PHARMS NY
Category: Irritable Bowel Syndrome

Lubiprostone (rINN, marketed under the trade name Amitiza among others) is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. The drug is owned by Mallinckrodt and is marketed by Takeda Pharmaceutical Company. The drug was developed by Sucampo Pharmaceuticals and approved by the Food and Drug Administration (FDA) in 2006.[1][2][3... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Lubiprostone 8 ug/1 Oral Capsule, Gelatin Coated
NDC: 0254-3028
Labeler:
Par Pharmaceutical Inc.
Lubiprostone 24 ug/1 Oral Capsule, Gelatin Coated
NDC: 0254-3029
Labeler:
Par Pharmaceutical Inc.
Lubiprostone 8 ug/1 Oral Capsule, Gelatin Coated
NDC: 0480-3479
Labeler:
Teva Pharmaceuticals, Inc.
Lubiprostone 24 ug/1 Oral Capsule, Gelatin Coated
NDC: 0480-4138
Labeler:
Teva Pharmaceuticals, Inc.
Lubiprostone 8 ug/1 Oral Capsule
NDC: 10370-266
Labeler:
Par Pharmaceutical, Inc.
Lubiprostone 24 ug/1 Oral Capsule
NDC: 10370-267
Labeler:
Par Pharmaceutical, Inc.
Lubiprostone 8 ug/1 Oral Capsule
NDC: 42291-475
Labeler:
Avkare
Lubiprostone 24 ug/1 Oral Capsule
NDC: 42291-476
Labeler:
Avkare
Lubiprostone 8 ug/1 Oral Capsule, Gelatin Coated
NDC: 43598-163
Labeler:
Dr. Reddy's Laboratories Inc.
Lubiprostone 24 ug/1 Oral Capsule, Gelatin Coated
NDC: 43598-168
Labeler:
Dr. Reddy's Laboratories Inc.
More Results

Related Brands

Drugs with the same active ingredients